{"id":"W4392551856","doi":"10.1111/jdv.19925","title":"Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (<scp>POETYK PSO</scp>‐1 and <scp>PSO</scp>‐2)","year":2024,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"","keywords":"Medicine; Placebo; Tolerability; Adverse effect; Discontinuation; Internal medicine; Apremilast; Psoriasis; Incidence (geometry); Population; Gastroenterology; Dermatology; Psoriatic arthritis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01331478,0.001784494,0.00440918,0.0009215847,0.0003968503,0.001486938,0.000625747,0.001376401,0.002479119],"category_scores_gemma":[0.009051119,0.0008488435,0.01047185,0.001062912,0.0004115461,0.0009156583,0.0007130393,0.001548715,0.0003466369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008469691,"about_ca_system_score_gemma":0.001442873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008299493,"about_ca_topic_score_gemma":0.002337487,"domain_scores_codex":[0.9946608,0.002790036,0.0007562719,0.0007553032,0.0008181828,0.0002195156],"domain_scores_gemma":[0.994703,0.002009572,0.001997689,0.0004295733,0.0004955958,0.000364603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6422371,0.001893736,0.02946323,0.01207629,0.1935727,0.000320059,0.000299974,0.005103799,0.01707033,0.0001167154,0.004659898,0.09318621],"study_design_scores_gemma":[0.387082,0.1022339,0.2129234,0.0009355978,0.275404,0.001622914,0.0001540833,0.002904332,0.007933591,0.0006314575,0.007933686,0.0002409623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.882144,0.09732712,0.005187186,0.0006887665,0.0002709209,0.003727872,0.007410529,0.0003500962,0.002893599],"genre_scores_gemma":[0.9795416,0.0108393,0.001750934,0.00047689,0.0002362331,0.001504679,0.005001804,0.00005516987,0.0005933699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01331478,"threshold_uncertainty_score":0.07041615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02740083357130022,"score_gpt":0.2952976864391373,"score_spread":0.2678968528678371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}